US Edition
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Standard Lithium secured a binding 10-year offtake with Trafigura for 8,000 tonnes per annum and attracted over $1 billion in project finance interest from export credit agencies.
- On Monday, March 30, 2026, Standard Lithium announced financial and operating results for the three-month and full-year periods ended December 31, 2025, highlighting progress on the South West Arkansas Project .
- The Arkansas Oil and Gas Commission granted unanimous approval for the Integration Application for the Reynolds Brine Unit, representing a key de-risking step for the SWA Project.
- Standard Lithium signed its first binding customer offtake agreement with Trafigura to supply 8,000 metric tonnes of lithium carbonate annually over a 10-year period, while receiving expressions of interest for over $1 billion in project finance.
- As of December 31, 2025, the company reported cash and working capital of $152.3 million and $147.6 million, respectively, compared to $20.9 million in cash equivalents versus $41.9 million the prior year.
- Management plans to reach a Final Investment Decision and begin construction on the SWA Project in 2026, with the long-term goal of producing over 100,000 tonnes of lithium chemicals annually in Texas.
14 Articles
14 Articles
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”),…
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial R
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 ap…
Cambridge Times
Simcoe.comStandard Lithium Reports Fourth Quarter and Full Year 2025 Results
Signed First Binding Customer Offtake Agreement with TrafiguraReceived Indications of Interest for Over $1 Billion in Project FinanceProvides an Update on Plans for a Final Investment Decision (“FID”) on the South West Arkansas Project (the “SWA Project”)
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium